Trade Idera Pharma - IDRA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Aceragen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.53 |
Open* | 0.46 |
1-Year Change* | -28.13% |
Day's Range* | 0.4 - 0.46 |
52 wk Range | 0.30-0.95 |
Average Volume (10 days) | 76.59K |
Average Volume (3 months) | 2.20M |
Market Cap | 21.41M |
P/E Ratio | -100.00K |
Shares Outstanding | 62.36M |
Revenue | N/A |
EPS | -0.34 |
Dividend (Yield %) | N/A |
Beta | 1.43 |
Next Earnings Date | Mar 29, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 17, 2023 | 0.40 | -0.06 | -13.04% | 0.46 | 0.47 | 0.40 |
Jan 13, 2023 | 0.53 | 0.00 | 0.00% | 0.53 | 0.53 | 0.52 |
Jan 12, 2023 | 0.53 | 0.02 | 3.92% | 0.51 | 0.54 | 0.50 |
Jan 11, 2023 | 0.48 | 0.04 | 9.09% | 0.44 | 0.49 | 0.41 |
Jan 10, 2023 | 0.44 | -0.17 | -27.87% | 0.61 | 0.64 | 0.41 |
Jan 9, 2023 | 0.64 | -0.04 | -5.88% | 0.68 | 0.68 | 0.63 |
Jan 6, 2023 | 0.66 | 0.03 | 4.76% | 0.63 | 0.69 | 0.63 |
Jan 5, 2023 | 0.63 | 0.12 | 23.53% | 0.51 | 0.65 | 0.51 |
Jan 4, 2023 | 0.53 | 0.10 | 23.26% | 0.43 | 0.53 | 0.43 |
Jan 3, 2023 | 0.43 | 0.03 | 7.50% | 0.40 | 0.45 | 0.39 |
Nov 15, 2022 | 0.38 | -0.02 | -5.00% | 0.40 | 0.40 | 0.38 |
Nov 11, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Nov 10, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Nov 8, 2022 | 0.39 | -0.02 | -4.88% | 0.41 | 0.41 | 0.39 |
Nov 7, 2022 | 0.40 | 0.00 | 0.00% | 0.40 | 0.41 | 0.39 |
Nov 4, 2022 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
Nov 3, 2022 | 0.41 | 0.00 | 0.00% | 0.41 | 0.42 | 0.39 |
Nov 2, 2022 | 0.39 | -0.05 | -11.36% | 0.44 | 0.45 | 0.39 |
Nov 1, 2022 | 0.45 | 0.04 | 9.76% | 0.41 | 0.46 | 0.40 |
Oct 31, 2022 | 0.41 | 0.03 | 7.89% | 0.38 | 0.44 | 0.38 |
Idera Pharma Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, June 8, 2023 | ||
Time (UTC) 20:15 | Country US
| Event Q1 2023 Idera Pharmaceuticals Inc Earnings Release Q1 2023 Idera Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, August 7, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q2 2023 Idera Pharmaceuticals Inc Earnings Release Q2 2023 Idera Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Idera Pharmaceuticals Inc Earnings Release Q3 2023 Idera Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 1.448 | 0.662 | 0.902 |
Revenue | 0 | 0 | 1.448 | 0.662 | 0.902 |
Total Operating Expense | 27.673 | 36.687 | 47.515 | 61.618 | 67.369 |
Selling/General/Admin. Expenses, Total | 9.976 | 11.915 | 12.481 | 15.42 | 16.716 |
Research & Development | 16.375 | 24.772 | 34.853 | 41.841 | 50.653 |
Operating Income | -27.673 | -36.687 | -46.067 | -60.956 | -66.467 |
Interest Income (Expense), Net Non-Operating | 6.961 | 0.134 | 0.516 | 1.075 | 0.483 |
Net Income Before Taxes | 98.091 | -112.662 | -56.515 | -59.881 | -65.984 |
Net Income After Taxes | 98.091 | -112.662 | -56.515 | -59.881 | -65.984 |
Net Income Before Extra. Items | 98.091 | -112.662 | -56.515 | -59.881 | -65.984 |
Net Income | 98.091 | -112.662 | -56.515 | -59.881 | -65.984 |
Total Adjustments to Net Income | -1.15 | 0 | -28.043 | ||
Income Available to Common Excl. Extra. Items | 96.941 | -112.662 | -84.558 | -59.881 | -65.984 |
Income Available to Common Incl. Extra. Items | 96.941 | -112.662 | -84.558 | -59.881 | -65.984 |
Diluted Net Income | 96.941 | -112.662 | -84.558 | -59.881 | -65.984 |
Diluted Weighted Average Shares | 50.127 | 33.821 | 28.545 | 26.601 | 19.6747 |
Diluted EPS Excluding Extraordinary Items | 1.93391 | -3.33113 | -2.96227 | -2.25108 | -3.35374 |
Diluted Normalized EPS | 1.96028 | -3.33113 | -2.95593 | -2.08729 | -3.35374 |
Total Extraordinary Items | 0 | ||||
Unusual Expense (Income) | 1.322 | 0 | 0.181 | 4.357 | |
Other, Net | 118.803 | -76.109 | -10.964 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 4.182 | 4.121 | 5.968 | 7.557 | 10.027 |
Selling/General/Admin. Expenses, Total | 2.398 | 2.017 | 2.331 | 2.472 | 3.156 |
Research & Development | 1.784 | 2.104 | 3.507 | 3.893 | 6.871 |
Operating Income | -4.182 | -4.121 | -5.968 | -7.557 | -10.027 |
Interest Income (Expense), Net Non-Operating | 0.004 | 0.002 | 0.003 | -0.006 | 6.962 |
Other, Net | 0 | 0 | 0 | 118.803 | |
Net Income Before Taxes | -4.178 | -4.119 | -5.965 | -7.563 | 115.738 |
Net Income After Taxes | -4.178 | -4.119 | -5.965 | -7.563 | 115.738 |
Net Income Before Extra. Items | -4.178 | -4.119 | -5.965 | -7.563 | 115.738 |
Net Income | -4.178 | -4.119 | -5.965 | -7.563 | 115.738 |
Income Available to Common Excl. Extra. Items | -4.178 | -5.269 | -5.965 | -7.563 | 115.738 |
Income Available to Common Incl. Extra. Items | -4.178 | -5.269 | -5.965 | -7.563 | 115.738 |
Diluted Net Income | -4.178 | -5.269 | -5.965 | -7.563 | 115.738 |
Diluted Weighted Average Shares | 52.893 | 52.842 | 52.74 | 49.909 | 70.98 |
Diluted EPS Excluding Extraordinary Items | -0.07899 | -0.09971 | -0.1131 | -0.15154 | 1.63057 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.07899 | -0.09971 | -0.11064 | -0.12765 | 1.63057 |
Unusual Expense (Income) | 0 | 0.13 | 1.192 | ||
Revenue | 0 | ||||
Total Adjustments to Net Income | 0 | -1.15 | |||
Dilution Adjustment | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 34.038 | 41.355 | 46.268 | 72.807 | 116.621 |
Cash and Short Term Investments | 32.545 | 37.728 | 42.793 | 71.431 | 112.629 |
Cash & Equivalents | 32.545 | 33.229 | 40.019 | 71.431 | 112.629 |
Short Term Investments | 0 | 4.499 | 2.774 | 0 | |
Prepaid Expenses | 1.493 | 3.627 | 3.475 | 1.376 | 3.992 |
Total Assets | 34.864 | 42.399 | 47.489 | 73.023 | 118.417 |
Property/Plant/Equipment, Total - Net | 0.756 | 0.974 | 1.151 | 0.207 | 1.472 |
Property/Plant/Equipment, Total - Gross | 1.553 | 1.807 | 1.925 | 0.871 | 5.932 |
Accumulated Depreciation, Total | -0.797 | -0.833 | -0.774 | -0.664 | -4.46 |
Long Term Investments | |||||
Other Long Term Assets, Total | 0.07 | 0.07 | 0.07 | 0.009 | 0.324 |
Total Current Liabilities | 4.862 | 7.027 | 54.517 | 9.018 | 10.109 |
Accounts Payable | 0.565 | 0.329 | 0.457 | 1.134 | 1.334 |
Accrued Expenses | 4.297 | 6.263 | 7.624 | 7.884 | 8 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.209 | |
Other Current Liabilities, Total | 0 | 0.435 | 46.436 | 0 | 0.566 |
Total Liabilities | 5.411 | 133.571 | 58.657 | 9.029 | 10.722 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 0.549 | 126.544 | 4.14 | 0.011 | 0.613 |
Total Equity | 29.453 | -91.172 | -11.168 | 63.994 | 107.695 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.053 | 0.038 | 0.03 | 0.027 | 0.196 |
Additional Paid-In Capital | 764.861 | 742.342 | 709.692 | 728.342 | 711.993 |
Retained Earnings (Accumulated Deficit) | -735.461 | -833.552 | -720.89 | -664.375 | -604.494 |
Other Equity, Total | 0 | ||||
Total Liabilities & Shareholders’ Equity | 34.864 | 42.399 | 47.489 | 73.023 | 118.417 |
Total Common Shares Outstanding | 52.818 | 38.291 | 29.672 | 27.188 | 24.4531 |
Total Preferred Shares Outstanding | 0.001 | 0.025 | 0.025 | 0.001 | 0.001 |
Redeemable Preferred Stock | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 29.362 | 34.038 | 38.299 | 43.475 | 47.018 |
Cash and Short Term Investments | 27.993 | 32.545 | 36.602 | 40.59 | 44.541 |
Cash & Equivalents | 27.993 | 32.545 | 36.602 | 40.59 | 44.541 |
Short Term Investments | 0 | 0 | 0 | ||
Prepaid Expenses | 1.369 | 1.493 | 1.697 | 2.885 | 2.477 |
Total Assets | 30.133 | 34.864 | 39.18 | 44.411 | 48.008 |
Property/Plant/Equipment, Total - Net | 0.701 | 0.756 | 0.811 | 0.866 | 0.92 |
Property/Plant/Equipment, Total - Gross | 1.502 | 1.553 | 1.603 | 1.652 | 1.716 |
Accumulated Depreciation, Total | -0.801 | -0.797 | -0.792 | -0.786 | -0.796 |
Other Long Term Assets, Total | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Total Current Liabilities | 3.796 | 4.862 | 5.566 | 6.029 | 4.996 |
Accounts Payable | 0.24 | 0.565 | 0.276 | 0.184 | 0.185 |
Accrued Expenses | 3.556 | 4.297 | 5.29 | 5.845 | 4.594 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0 | 0 | 0.217 | |
Total Liabilities | 4.29 | 5.411 | 6.169 | 6.685 | 5.704 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.494 | 0.549 | 0.603 | 0.656 | 0.708 |
Total Equity | 25.843 | 29.453 | 33.011 | 37.726 | 42.304 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.053 | 0.053 | 0.053 | 0.052 | 0.046 |
Additional Paid-In Capital | 765.429 | 764.861 | 764.3 | 763.051 | 760.072 |
Retained Earnings (Accumulated Deficit) | -739.639 | -735.461 | -731.342 | -725.377 | -717.814 |
Total Liabilities & Shareholders’ Equity | 30.133 | 34.864 | 39.18 | 44.411 | 48.008 |
Total Common Shares Outstanding | 52.924 | 52.818 | 52.777 | 52.115 | 46.537 |
Total Preferred Shares Outstanding | 0.001 | 0.001 | 0.001 | 0.001 | 0.011 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | 98.091 | -112.662 | -56.515 | -59.881 | -65.984 |
Cash From Operating Activities | -24.597 | -33.772 | -44.498 | -51.916 | -55.259 |
Cash From Operating Activities | 0.022 | 0.061 | 0.12 | 0.432 | 0.746 |
Non-Cash Items | -123.098 | 79.947 | 15.154 | 6.248 | 10.964 |
Cash Interest Paid | 0.005 | 0 | 0 | 0.009 | 0.042 |
Changes in Working Capital | 0.388 | -1.118 | -3.257 | 1.285 | -0.985 |
Cash From Investing Activities | 4.5 | -1.687 | -2.402 | 0.215 | 28.064 |
Capital Expenditures | 0 | -0.008 | -0.011 | -0.075 | -0.206 |
Other Investing Cash Flow Items, Total | 4.5 | -1.679 | -2.391 | 0.29 | 28.27 |
Cash From Financing Activities | 19.413 | 28.669 | 15.488 | 10.192 | 59.157 |
Issuance (Retirement) of Stock, Net | 19.848 | 28.886 | 5.422 | 10.409 | 59.46 |
Issuance (Retirement) of Debt, Net | -0.435 | -0.217 | -0.006 | -0.217 | -0.303 |
Net Change in Cash | -0.684 | -6.79 | -31.412 | -41.509 | 31.962 |
Financing Cash Flow Items | 0 | 10.072 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.178 | 98.091 | 102.21 | 108.175 | 115.738 |
Cash From Operating Activities | -4.568 | -24.597 | -20.545 | -15.85 | -9.591 |
Cash From Operating Activities | 0.004 | 0.022 | 0.017 | 0.011 | 0.006 |
Non-Cash Items | 0.567 | -123.098 | -123.667 | -124.142 | -124.609 |
Cash Interest Paid | 0 | 0.005 | 0.005 | 0.005 | 0.003 |
Changes in Working Capital | -0.961 | 0.388 | 0.895 | 0.106 | -0.726 |
Cash From Investing Activities | 0 | 4.5 | 4.5 | 4.5 | 4.5 |
Capital Expenditures | 0 | 0 | 0 | ||
Other Investing Cash Flow Items, Total | 0 | 4.5 | 4.5 | 4.5 | 4.5 |
Cash From Financing Activities | 0.016 | 19.413 | 19.418 | 18.711 | 16.403 |
Issuance (Retirement) of Stock, Net | 0.016 | 19.848 | 19.853 | 19.146 | 16.621 |
Issuance (Retirement) of Debt, Net | 0 | -0.435 | -0.435 | -0.435 | -0.218 |
Net Change in Cash | -4.552 | -0.684 | 3.373 | 7.361 | 11.312 |
Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Idera Pharma Company profile
About Idera Pharmaceuticals Inc
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Idera Pharmaceuticals Inc revenues was not reported. Net income totaled $102.2M vs. loss of $36M. Net income reflects Future tranche right revaluation gain increase from $7M (expense) to $118.8M (income), Warrant revaluation gain increase from $188K to $7M (income), Research and development - Balancing decrease of 28% to $13.8M (expense).
Equity composition
Common Stock $.001 Par, 02/12, 70M auth., 27,637,007 issd., Insiders control 15.21%. IPO:2/96, 5,750,000 shs. @ $10 by Lehman Brothers. 12/97, 1-for-5 reverse split. FY'00 Q's are RES. 8/03 20,053,022 shs. issd. in a private placement. 9/05, 12/07, Company delisted from AMEX to NASDAQ.
Industry: | Biotechnology & Medical Research (NEC) |
505 Eagleview Boulevard
Suite 212
EXTON
PENNSYLVANIA 19341
US
Income Statement
- Annual
- Quarterly
News

USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com